The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: The phase 2 FIREFLY-1 trial

Authors

Lindsay B Kilburn, Children's National Hospital
Mohamed S Abdelbaki, Washington University School of Medicine in St. Louis
et al.

Journal

Nature Medicine

Publication Date

1-1-2024

Volume

30

Issue

1

First Page

207

Last Page

217

Document Type

Open Access Publication

DOI

10.1038/s41591-023-02668-y

Rights and Permissions

Kilburn, L.B., Khuong-Quang, DA., Hansford, J.R. et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 30, 207–217 (2024). https://doi.org/10.1038/s41591-023-02668-y This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Kilburn, Lindsay B; Abdelbaki, Mohamed S; and et al., "The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: The phase 2 FIREFLY-1 trial." Nature Medicine. 30, 1. 207 - 217. (2024).
https://digitalcommons.wustl.edu/oa_4/3310

Additional Links

Supplemental material is available for this article at publisher site.